Rosenblatt analyst Barton Crockett maintains Snap (NYSE:SNAP) with a Neutral and lowers the price target from $13 to $8.
FDA Issues Partial Clinical Hold On Merck Germany’s Multiple Sclerosis Study
The FDA has placed a partial clinical hold on initiating new patients on Germany’s Merck KGaA’s (OTC:MKGAF) (OTC:MKKGY) evobrutinib and patients with…